Epoch Investment Partners’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-6,308
| Closed | -$1.09M | – | 224 |
|
|
2026
Q1 | $1.09M | Sell |
6,308
-21,131
| -77% | -$3.92M | 0.01% | 221 |
|
|
2025
Q4 | $5.47M | Buy |
27,439
+901
| +3% | +$163K | 0.03% | 205 |
|
|
2025
Q3 | $4.15M | Buy |
26,538
+22,714
| +594% | +$3.61M | 0.02% | 210 |
|
|
2025
Q2 | $580K | Buy |
+3,824
| New | +$510K | ﹤0.01% | 264 |
|
|
2025
Q1 | – | Sell |
-49,066
| Closed | -$9.06M | – | 282 |
|
|
2024
Q4 | $9.06M | Buy |
49,066
+39,972
| +440% | +$7.7M | 0.04% | 202 |
|
|
2024
Q3 | $1.79M | Sell |
9,094
-262,050
| -97% | -$54.5M | 0.01% | 264 |
|
|
2024
Q2 | $56M | Buy |
271,144
+23,643
| +10% | +$5.36M | 0.26% | 139 |
|
|
2024
Q1 | $67.1M | Buy |
247,501
+238,766
| +2,733% | +$57M | 0.3% | 117 |
|
|
2023
Q4 | $2.06M | Sell |
8,735
-1,102
| -11% | -$217K | 0.01% | 311 |
|
|
2023
Q3 | $1.93M | Buy |
9,837
+7,206
| +274% | +$1.48M | 0.01% | 314 |
|
|
2023
Q2 | $553K | Sell |
2,631
-44
| -2% | -$8.75K | ﹤0.01% | 398 |
|
|
2023
Q1 | $540K | Sell |
2,675
-4,725
| -64% | -$1.07M | ﹤0.01% | 392 |
|
|
2022
Q4 | $1.61M | Buy |
7,400
+1,431
| +24% | +$312K | 0.01% | 324 |
|
|
2022
Q3 | $1.18M | Sell |
5,969
-22,325
| -79% | -$4.82M | 0.01% | 347 |
|
|
2022
Q2 | $6.05M | Buy |
28,294
+693
| +3% | +$169K | 0.04% | 304 |
|
|
2022
Q1 | $7.84M | Buy |
27,601
+3,237
| +13% | +$998K | 0.04% | 293 |
|
|
2021
Q4 | $9.18M | Sell |
24,364
-9,956
| -29% | -$3.87M | 0.05% | 281 |
|
|
2021
Q3 | $14.2M | Hold |
34,320
| – | – | 0.08% | 227 |
|
|
2021
Q2 | $12.7M | Sell |
34,320
-218,880
| -86% | -$73.1M | 0.07% | 232 |
|
|
2021
Q1 | $73.4M | Sell |
253,200
-214,124
| -46% | -$59.5M | 0.34% | 105 |
|
|
2020
Q4 | $117M | Sell |
467,324
-221,125
| -32% | -$52.7M | 0.54% | 58 |
|
|
2020
Q3 | $156M | Sell |
688,449
-50,900
| -7% | -$10.6M | 0.78% | 37 |
|
|
2020
Q2 | $129M | Sell |
739,349
-84,312
| -10% | -$13.5M | 0.67% | 52 |
|
|
2020
Q1 | $104M | Buy |
823,661
+112,014
| +16% | +$16.8M | 0.63% | 53 |
|
|
2019
Q4 | $109M | Sell |
711,647
-12,996
| -2% | -$1.8M | 0.47% | 86 |
|
|
2019
Q3 | $95.9M | Sell |
724,643
-15,557
| -2% | -$2.09M | 0.44% | 93 |
|
|
2019
Q2 | $105M | Buy |
740,200
+165,494
| +29% | +$22.4M | 0.47% | 87 |
|
|
2019
Q1 | $83.5M | Buy |
574,706
+230,105
| +67% | +$30.2M | 0.36% | 100 |
|
|
2018
Q4 | $39M | Buy |
+344,601
| New | +$43.1M | 0.18% | 127 |
|
Other funds holding CRL
AI
Epoch Investment Partners's CRL Position: Q2 2026 in Review
Epoch Investment Partners sold out of Charles River Laboratories (CRL) in Q2 2026, closing a stake of 6,308 shares — an estimated $1.09M sold.
Epoch Investment Partners first reported a position in CRL in Q4 2018 and held it in 29 quarters. The position peaked at $156M in Q3 2020. 568 funds tracked by Wall St. Rank hold CRL as of Q2 2026.
- Epoch Investment Partners reported no remaining Charles River Laboratories position as of Q2 2026 after selling out during the quarter.
- Epoch Investment Partners sold 6,308 Charles River Laboratories shares in Q2 2026, an estimated $1.09M.
- Epoch Investment Partners first reported a position in Charles River Laboratories in Q4 2018 and held it in 29 quarters.
- Epoch Investment Partners's Charles River Laboratories position peaked at $156M in Q3 2020.
- 568 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.
Based on Epoch Investment Partners's 13F filing for Q2 2026, filed 13 Aug 2026.